CASI Pharmaceuticals is an innovative biopharmaceutical company listed on the NASDAQ. It was founded in 1991 as EntreMed and officially changed its name to CASI Pharmaceuticals in 2014. Headquartered in Maryland, United States, the company is dedicated to the development and commercialization of innovative drugs to address unmet medical needs worldwide.

CASI is an innovative biopharmaceutical company developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases.

At CASI, they are striving to bring a first-in-class and best-in-class therapy to alleviate the burden of AMR on affected patients.

CASI is also focused on developing CID-103, an investigational monoclonal antibody. Its targets include B memory, plasmablasts, and B plasma cells. The anti-CD38 approach aims to address limitations seen with CD19 and CD20-targeted therapies, which do not deplete persistent plasma cells—cells that may contribute to organ transplant rejection by generating antibodies which attack the donor kidney.